The vaccine adverse event reporting system and vaccine safety research in the genomics era

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Advances in genetics hold promise for integrating genomics into vaccine safety research. Given the rarity of many vaccine adverse effects, and the challenges in finding sufficient numbers of patients to study, consideration should be given to employing the Vaccine Adverse Event Reporting System (VAERS) for genetic studies of vaccine adverse events. VAERS could be used to build a repository of biospecimens allowing for the systematic evaluation of vaccine adverse events. If successful, such research would enable the identification of specific subgroups of people at particularly increased risk for adverse events.

Original languageEnglish (US)
Pages (from-to)1162-1164
Number of pages3
JournalVaccine
Volume30
Issue number6
DOIs
StatePublished - Feb 1 2012

Fingerprint

Genomics
Vaccines
vaccines
genomics
Safety
Research
genetic improvement
adverse effects

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

The vaccine adverse event reporting system and vaccine safety research in the genomics era. / Davis, Robert.

In: Vaccine, Vol. 30, No. 6, 01.02.2012, p. 1162-1164.

Research output: Contribution to journalArticle

@article{cc4c72b456d142fa8b062077d21df297,
title = "The vaccine adverse event reporting system and vaccine safety research in the genomics era",
abstract = "Advances in genetics hold promise for integrating genomics into vaccine safety research. Given the rarity of many vaccine adverse effects, and the challenges in finding sufficient numbers of patients to study, consideration should be given to employing the Vaccine Adverse Event Reporting System (VAERS) for genetic studies of vaccine adverse events. VAERS could be used to build a repository of biospecimens allowing for the systematic evaluation of vaccine adverse events. If successful, such research would enable the identification of specific subgroups of people at particularly increased risk for adverse events.",
author = "Robert Davis",
year = "2012",
month = "2",
day = "1",
doi = "10.1016/j.vaccine.2011.12.018",
language = "English (US)",
volume = "30",
pages = "1162--1164",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "6",

}

TY - JOUR

T1 - The vaccine adverse event reporting system and vaccine safety research in the genomics era

AU - Davis, Robert

PY - 2012/2/1

Y1 - 2012/2/1

N2 - Advances in genetics hold promise for integrating genomics into vaccine safety research. Given the rarity of many vaccine adverse effects, and the challenges in finding sufficient numbers of patients to study, consideration should be given to employing the Vaccine Adverse Event Reporting System (VAERS) for genetic studies of vaccine adverse events. VAERS could be used to build a repository of biospecimens allowing for the systematic evaluation of vaccine adverse events. If successful, such research would enable the identification of specific subgroups of people at particularly increased risk for adverse events.

AB - Advances in genetics hold promise for integrating genomics into vaccine safety research. Given the rarity of many vaccine adverse effects, and the challenges in finding sufficient numbers of patients to study, consideration should be given to employing the Vaccine Adverse Event Reporting System (VAERS) for genetic studies of vaccine adverse events. VAERS could be used to build a repository of biospecimens allowing for the systematic evaluation of vaccine adverse events. If successful, such research would enable the identification of specific subgroups of people at particularly increased risk for adverse events.

UR - http://www.scopus.com/inward/record.url?scp=84856320123&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856320123&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2011.12.018

DO - 10.1016/j.vaccine.2011.12.018

M3 - Article

VL - 30

SP - 1162

EP - 1164

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 6

ER -